Are you protecting your patients 50 years and older with SHINGRIX?1 Review the profiles below to see the types of potential patients for SHINGRIX.
Not actual patients
Luis, Age 56
He always prioritizes taking care of others over himself.
Who's in Luis’s Life?
- His wife, 3 children, and parents who live with him
- His team at the local grocery store
- Recipients of his Food For The Needy program
Lifestyle: He does not eat a healthy diet and is usually too busy to exercise
Medical History: Type 2 diabetes
Interaction With HCP: Reluctant about visiting. Only goes a few times a year to review A1C levels
Recommendation Opportunity: During his A1C check
Recommend SHINGRIX Because: Prevention isn't on his radar
John, Age 66
He's retired but he's just getting started.
Who's in John’s Life?
- His wife and 2 adult children
- He has taken a big role in his autistic grandson's life
- His adopted rescue dogs
Lifestyle: He always makes time to walk his 2 dogs
Medical History: Knee replacement
Interaction With HCP: Since his recent knee replacement, John started seeing his doctor on a yearly basis, as he is more diligent about keeping his weight down and living healthy
Recommendation Opportunity: During regular office visit
Recommend SHINGRIX Because: He doesn’t want shingles to affect any part of his retirement
Betty, Age 80
With so much to manage with her health, she's not thinking about shingles.
Who's in Betty’s Life?
- Her 4 children and 8 grandchildren
- Her close circle of friends nearby
Lifestyle: She walks in the park when she can and maintains a healthy Mediterranean diet to help manage her cholesterol
Medical History: High cholesterol, macular degeneration, hypertension
Interaction With HCP: Overwhelmed with seeing multiple specialists, doesn't always keep up with GP visits
Recommendation Opportunity: During a referral visit
Recommend SHINGRIX Because: She doesn't want to worry about shingles, too
*Data from the phase 3 ZOE-50 (≥50 years of age) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346,respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.1,5 See study designs on the Efficacy page for details.